NCI-H358/RFP-Luciferase cells are derived from the human non-small cell lung cancer (NSCLC) NCI-H358 cell line by stably integration of a constitutive RFP-Firefly luciferase stably expression construct. The NCI-H358 cell line is notable for its mutations in the KRAS gene. NCI-H358 cells have been used to study mechanisms of cancer biology, particularly those related to KRAS signaling, as well as to evaluate the efficacy of targeted therapies and novel compounds against KRAS-mutant cancers. NCI-H358/RFP-Luciferse cells stably stably express RFP and Firefly luciferase, can be used for in vitro assays and in vivo imaging.